دورية أكاديمية

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA

التفاصيل البيبلوغرافية
العنوان: P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
المؤلفون: Venditti, Adriano, Piciocchi, Alfonso, Maurillo, Luca, Ilaria Del Principe, Maria, Palmieri, Raffaele, Soddu, Stefano, Moretti, Federico, Salutari, Prassede, Martelli, Maurizio, Paola Martelli, Maria, Luppi, Mario, Pulsoni, Alessandro, Zaja, Francesco, Cairoli, Roberto, Pane, Fabrizio, Siragusa, Sergio, Bassan, Renato, Rondoni, Michela, Mirabile, Milena, Mulè, Antonino, Beltrami, Germana, Zappasodi, Patrizia, Cudillo, Laura, Mengarelli, Andrea, Curti, Antonio, Ferrara, Felicetto, Rossi, Giovanni, Audisio, Ernesta, Spinosa, Giuseppina, Tieghi, Alessia, Bocchia, Monica, Martini, Vincenza, Califano, Catello, Rigacci, Luigi, Tafuri, Agostino, Gottardi, Michele, Fazi, Paola, Vignetti, Marco, Buccisano, Francesco
المصدر: HemaSphere ; volume 7, issue S3, page e8415389 ; ISSN 2572-9241
بيانات النشر: Wiley
سنة النشر: 2023
المجموعة: Wiley Online Library (Open Access Articles via Crossref)
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1097/01.hs9.0000968928.84153.89
DOI: 10.1097/01.HS9.0000968928.84153.89
الإتاحة: https://doi.org/10.1097/01.hs9.0000968928.84153.89Test
حقوق: http://creativecommons.org/licenses/by-nc-nd/4.0Test/
رقم الانضمام: edsbas.2C766A91
قاعدة البيانات: BASE